You just read:

Oral Alpha-4-Beta-7 Integrin Antagonist PN-943 Demonstrates Superior Dose-Related Target Engagement Activity to PTG-100 in Single Ascending Dose Phase 1 Study

News provided by

Protagonist Therapeutics, Inc.

May 14, 2019, 07:00 ET